IP Verse

Compounds And Compositions For Intracellular Delivery Of Agents - EP3394030

The patent EP3394030 was granted to Moderna on Feb 12, 2025. The application was originally filed on Dec 22, 2016 under application number EP16831870A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3394030

MODERNA
Application Number
EP16831870A
Filing Date
Dec 22, 2016
Status
Patent Maintained As Amended
Jan 10, 2025
Grant Date
Feb 12, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANTSep 22, 2022BOULT WADE TENNANTADMISSIBLE

Patent Citations (118) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP2610340
DESCRIPTIONEP2610341
DESCRIPTIONUS2005222064
DESCRIPTIONUS2007048776
DESCRIPTIONUS2009093049
DESCRIPTIONUS2009226470
DESCRIPTIONUS2011124100
DESCRIPTIONUS2013177581
DESCRIPTIONUS4270537
DESCRIPTIONUS4596556
DESCRIPTIONUS4790824
DESCRIPTIONUS4886499
DESCRIPTIONUS4940460
DESCRIPTIONUS4941880
DESCRIPTIONUS5015235
DESCRIPTIONUS5064413
DESCRIPTIONUS5141496
DESCRIPTIONUS5190521
DESCRIPTIONUS5312335
DESCRIPTIONUS5328483
DESCRIPTIONUS5334144
DESCRIPTIONUS5339163
DESCRIPTIONUS5383851
DESCRIPTIONUS5417662
DESCRIPTIONUS5466220
DESCRIPTIONUS5480381
DESCRIPTIONUS5503627
DESCRIPTIONUS5520639
DESCRIPTIONUS5527288
DESCRIPTIONUS5569189
DESCRIPTIONUS5599302
DESCRIPTIONUS5649912
DESCRIPTIONUS5704911
DESCRIPTIONUS5893397
DESCRIPTIONUS5993412
DESCRIPTIONUS6310197
DESCRIPTIONUS6849405
DESCRIPTIONUS7183395
DESCRIPTIONUS7456273
DESCRIPTIONUS7468275
DESCRIPTIONUS8519110
DESCRIPTIONWO0155369
DESCRIPTIONWO0155371
DESCRIPTIONWO02098443
DESCRIPTIONWO03051401
DESCRIPTIONWO2004004743
DESCRIPTIONWO2005016376
DESCRIPTIONWO2006024518
DESCRIPTIONWO2006122828
DESCRIPTIONWO2007025008
DESCRIPTIONWO2007095976
DESCRIPTIONWO2008014979
DESCRIPTIONWO2008016473
DESCRIPTIONWO2008052770
DESCRIPTIONWO2008077592
DESCRIPTIONWO2008083949
DESCRIPTIONWO2008127688
DESCRIPTIONWO2009030481
DESCRIPTIONWO2009075886
DESCRIPTIONWO2009095226
DESCRIPTIONWO2009127230
DESCRIPTIONWO2010037539
DESCRIPTIONWO2010088927
DESCRIPTIONWO2011015347
DESCRIPTIONWO2011026641
DESCRIPTIONWO2011069586
DESCRIPTIONWO2011144358
DESCRIPTIONWO2012009644
DESCRIPTIONWO2012013326
DESCRIPTIONWO2012019780
DESCRIPTIONWO2012089338
DESCRIPTIONWO2012113513
DESCRIPTIONWO2012116810
DESCRIPTIONWO2012116811
DESCRIPTIONWO2013103659
DESCRIPTIONWO2013113501
DESCRIPTIONWO2013113502
DESCRIPTIONWO2013113736
DESCRIPTIONWO2013120497
DESCRIPTIONWO2013120498
DESCRIPTIONWO2013120499
DESCRIPTIONWO2013120500
DESCRIPTIONWO2013120626
DESCRIPTIONWO2013120627
DESCRIPTIONWO2013120628
DESCRIPTIONWO2013120629
DESCRIPTIONWO2013143698
DESCRIPTIONWO2013143699
DESCRIPTIONWO2013143700
DESCRIPTIONWO2013174409
DESCRIPTIONWO2014127917
DESCRIPTIONWO2015002667
DESCRIPTIONWO2015011633
DESCRIPTIONWO2015024664
DESCRIPTIONWO2015024665
DESCRIPTIONWO2015024666
DESCRIPTIONWO2015024667
DESCRIPTIONWO2015024668
DESCRIPTIONWO2015024669
DESCRIPTIONWO2015062738
DESCRIPTIONWO2015101414
DESCRIPTIONWO2015101415
DESCRIPTIONWO2015101416
DESCRIPTIONWO2015199952
DESCRIPTIONWO2016176330
DESCRIPTIONWO9713537
DESCRIPTIONWO9737705
DESCRIPTIONWO9924595
DESCRIPTIONWO9934850
INTERNATIONAL-SEARCH-REPORTUS2012295832
INTERNATIONAL-SEARCH-REPORTWO2009086558
INTERNATIONAL-SEARCH-REPORTWO2009129395
INTERNATIONAL-SEARCH-REPORTWO2015199952
INTERNATIONAL-SEARCH-REPORTWO2016118724
OPPOSITIONUS2012295832
OPPOSITIONWO2010053572
OPPOSITIONWO2011017548
OPPOSITIONWO2014028487

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AKINC, A. ET AL., MOL. THER., (2010), vol. 18, pages 1357 - 1364-
DESCRIPTION- BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCE, (1977), vol. 66, pages 1 - 19-
DESCRIPTION- CHAPPELL ET AL., PROC. NATL. ACAD. SCI. USA, (2004), vol. 101, pages 9590 - 9594-
DESCRIPTION- DONG, Y. ET AL., PNAS, (2014), vol. 111, pages 3955 - 3960-
DESCRIPTION- KORE ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, (2013), vol. 21, pages 4570 - 4574-
DESCRIPTION- PANEK ET AL., NUCLEIC ACIDS RESEARCH, (2013), pages 1 - 10-
DESCRIPTION- Remington's Pharmaceutical Sciences, 17th ed., MACK PUBLISHING COMPANY, (1985), page 1418-
DESCRIPTION- ZHOU ET AL., PNAS, (2005), vol. 102, pages 6273 - 6278-
INTERNATIONAL-SEARCH-REPORT- Alex K.K. Leung ET AL, "Lipid Nanoparticles for Short Interfering RNA Delivery", Advances in Genetics, US, Academic Press, (20140101), vol. 88, pages 71 - 110, doi:10.1016/B978-0-12-800148-6.00004-3, ISSN 0065-2660, XP055348135 [A] 1-120,141-150,342-347,354-389,391-399,401-412,414-418,420-436 * the whole document *
INTERNATIONAL-SEARCH-REPORT- R MÜLLER ET AL, "Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS., NL, (20000703), vol. 50, no. 1, doi:10.1016/S0939-6411(00)00087-4, ISSN 0939-6411, pages 161 - 177, XP055348127 [A] 1-120,141-150,342-347,354-389,391-399,401-412,414-418,420-436 * the whole document *
OPPOSITION- ABRAMS et al., "Evaluation of Efficacy, Biodistribution, and Inflammation for a Potent siRNA Nanoparticle: Effect of Dexamethasone Co- treatment", Molecular Therapy, (20100000), vol. 18, doi:10.1038/mt.2009.208, pages 171 - 180, XP007918345
OPPOSITION- Tao Weikang, Mao Xianzhi, Davide Joseph P, Ng Bruce, Cai Mingmei, Burke Paul A, Sachs Alan B, Sepp-Lorenzino Laura, "Mechanistically Probing Lipid-siRNA Nanoparticle-associated Toxicities Identifies Jak Inhibitors Effective in Mitigating Multifaceted Toxic Responses", Molecular Therapy, Elsevier Inc., US, US , (20110301), vol. 19, no. 3, doi:10.1038/mt.2010.282, ISSN 1525-0016, pages 567 - 575, XP055969296
OPPOSITION- HAN et al., "An ionizable lipid toolbox for RNA delivery", Nature Communications, (20210000), vol. 12, doi:10.1038/s41467-021-27493-0, XP055938542
OPPOSITION- Yuen Tam, Chen Sam, Cullis Pieter, "Advances in Lipid Nanoparticles for siRNA Delivery", Pharmaceutics, (20130901), vol. 5, no. 3, doi:10.3390/pharmaceutics5030498, pages 498 - 507, XP055246895

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents